Arthur Peyrottes, Guillaume Ploussard, Paul Sargos, Eric Barret, Michael Baboudjian
{"title":"局部前列腺癌的中间风险难题:一个群体,许多现实。","authors":"Arthur Peyrottes, Guillaume Ploussard, Paul Sargos, Eric Barret, Michael Baboudjian","doi":"10.1016/j.euo.2025.09.017","DOIUrl":null,"url":null,"abstract":"<p><p>For intermediate-risk prostate cancer, definitions remain inconsistent and management varies. Greater precision is urgently needed via optimal use of existing tools and integration of emerging innovations to harmonise care and improve outcomes for this most common disease category.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":9.3000,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Conundrum of Intermediate Risk in Localised Prostate Cancer: One Group, Many Realities.\",\"authors\":\"Arthur Peyrottes, Guillaume Ploussard, Paul Sargos, Eric Barret, Michael Baboudjian\",\"doi\":\"10.1016/j.euo.2025.09.017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>For intermediate-risk prostate cancer, definitions remain inconsistent and management varies. Greater precision is urgently needed via optimal use of existing tools and integration of emerging innovations to harmonise care and improve outcomes for this most common disease category.</p>\",\"PeriodicalId\":12256,\"journal\":{\"name\":\"European urology oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":9.3000,\"publicationDate\":\"2025-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European urology oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.euo.2025.09.017\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euo.2025.09.017","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
The Conundrum of Intermediate Risk in Localised Prostate Cancer: One Group, Many Realities.
For intermediate-risk prostate cancer, definitions remain inconsistent and management varies. Greater precision is urgently needed via optimal use of existing tools and integration of emerging innovations to harmonise care and improve outcomes for this most common disease category.
期刊介绍:
Journal Name: European Urology Oncology
Affiliation: Official Journal of the European Association of Urology
Focus:
First official publication of the EAU fully devoted to the study of genitourinary malignancies
Aims to deliver high-quality research
Content:
Includes original articles, opinion piece editorials, and invited reviews
Covers clinical, basic, and translational research
Publication Frequency: Six times a year in electronic format